CA2643802A1 - Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations - Google Patents

Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations Download PDF

Info

Publication number
CA2643802A1
CA2643802A1 CA002643802A CA2643802A CA2643802A1 CA 2643802 A1 CA2643802 A1 CA 2643802A1 CA 002643802 A CA002643802 A CA 002643802A CA 2643802 A CA2643802 A CA 2643802A CA 2643802 A1 CA2643802 A1 CA 2643802A1
Authority
CA
Canada
Prior art keywords
administration
receptors
receptor
ligand
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002643802A
Other languages
English (en)
Inventor
Alexander Michalow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2643802A1 publication Critical patent/CA2643802A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
CA002643802A 2006-02-27 2007-02-27 Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations Abandoned CA2643802A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77719006P 2006-02-27 2006-02-27
US60/777,190 2006-02-27
US85818606P 2006-11-09 2006-11-09
US60/858,186 2006-11-09
PCT/US2007/004959 WO2007100775A2 (fr) 2006-02-27 2007-02-27 Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations

Publications (1)

Publication Number Publication Date
CA2643802A1 true CA2643802A1 (fr) 2007-09-07

Family

ID=38459618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002643802A Abandoned CA2643802A1 (fr) 2006-02-27 2007-02-27 Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations

Country Status (5)

Country Link
EP (1) EP2001495A4 (fr)
JP (1) JP2009528289A (fr)
AU (1) AU2007221135A1 (fr)
CA (1) CA2643802A1 (fr)
WO (1) WO2007100775A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
JP5415767B2 (ja) 2005-11-10 2014-02-12 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ 依存症及び他の精神神経疾患の治療のための組成物及び方法
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
WO2009001764A1 (fr) * 2007-06-22 2008-12-31 Toray Industries, Inc. Traitement ou prevention du syndrome du dysfonctionnement de l'integration
WO2009109001A1 (fr) * 2008-03-04 2009-09-11 Adelaide Research & Innovation Pty Ltd Procédé de prévention et/ou de traitement d’une maladie, d’une condition ou d’un état associés à une fonction réduite des neurones dopaminergiques
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CA2785056A1 (fr) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methodes et compositions pour le traitement de la detresse dysfonctionnelle et l'augmentation de la securite et de l'efficacite de medicaments specifiques
CA2802957A1 (fr) 2010-06-16 2011-12-22 Embera Neurotherapeutics, Inc Compositions et procedes pour le traitement de l'addiction, des troubles psychiatriques, et d'une maladie neurodegenerative
CN103313601B (zh) * 2010-06-29 2015-04-08 宾夕法尼亚大学理事会 salvinorin组合物及其用途
US11000505B2 (en) * 2010-06-29 2021-05-11 The Trustees Of The University Of Pennsylvania Salvinorin compositions and uses thereof
PT2925757T (pt) 2012-11-19 2018-01-09 Novartis Ag Compostos e composições para o tratamento de doenças parasitárias
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
EP2945627A4 (fr) * 2013-01-21 2016-11-30 Avant Derma Pte Ltd Utilisation d'antagonistes sélectifs du récepteur delta-opioïde et ligands spécifiques de récepteurs sensoriels
US9663488B2 (en) * 2013-01-28 2017-05-30 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US20150342946A1 (en) 2013-01-30 2015-12-03 Pharmorx Therapeutics, Inc. Treatments For Depression And Other Diseases With A Low Dose Agent
WO2014170351A1 (fr) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalméfène pour le traitement de patients atteints de trouble de l'humeur
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
WO2016195723A1 (fr) * 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Méthodes de traitement d'états médiés par la substance p
CN106008487B (zh) 2015-12-31 2019-08-09 北京理工大学 一种二苯乙烯类衍生物及其制备方法
WO2018102552A1 (fr) 2016-11-30 2018-06-07 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
BR112019018700A2 (pt) 2017-03-10 2020-04-07 Embera Neurotherapeutics Inc composições farmacêuticas e seus usos
US10729693B2 (en) * 2018-03-02 2020-08-04 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP150098A0 (en) * 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
KR20040014926A (ko) * 2000-07-19 2004-02-18 브리스톨-마이어스 스퀴브 파마 컴파니 조합 요법에서의 ｃｒｆ２ 리간드
US6437093B1 (en) * 2000-11-28 2002-08-20 Milkhaus Laboratory, Inc. Methods of treatment comprising administration of Substance P
US7439264B2 (en) * 2002-02-08 2008-10-21 President And Fellows Of Harvard College Therapeutic compounds
CA2580694A1 (fr) * 2004-09-23 2006-03-30 Alexander Michalow Methodes permettant de reguler les systemes de neurotransmetteurs en induisant des contre-adaptations

Also Published As

Publication number Publication date
AU2007221135A1 (en) 2007-09-07
EP2001495A2 (fr) 2008-12-17
WO2007100775A3 (fr) 2008-11-27
JP2009528289A (ja) 2009-08-06
WO2007100775A2 (fr) 2007-09-07
EP2001495A4 (fr) 2010-12-08

Similar Documents

Publication Publication Date Title
CA2643802A1 (fr) Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations
US20120208751A1 (en) Methods for Regulating Neurotransmitter Systems by Inducing Counteradaptations
AU2005286733B2 (en) Methods for regulating neurotransmitter systems by inducing counteradaptations
JP6453931B2 (ja) 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
DE69930552T2 (de) Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
Bartolini et al. Analgesic and antineuropathic drugs acting through central cholinergic mechanisms
Yamamoto et al. Involvement of substance P in the development of cisplatin‐induced acute and delayed pica in rats
CN101432011A (zh) 通过诱导逆适应调节神经递质系统的方法
Shinpo et al. The role of area postrema neurons expressing H-channels in the induction mechanism of nausea and vomiting
US20110034565A1 (en) Psycho-pharmaceuticals
RU2322977C1 (ru) Синтетическое анальгетическое средство и способ лечения на основе этого средства
Levi et al. A review of chemical agents in the pharmacotherapy of addiction
Koob et al. Psychostimulants
KR101969667B1 (ko) 정신 의학적 증상의 치료를 위한 ｄ-메타돈
CN1527711A (zh) 用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物
US9023788B2 (en) Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
Mahesh et al. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods
Bambico et al. A key role for prefrontocortical small conductance calcium-activated potassium channels in stress adaptation and rapid antidepressant response
US6380216B1 (en) Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders
Felicio et al. Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response
CN1767833A (zh) 卡马西平衍生物在治疗痴呆患者的激动中的用途
Mehta et al. Acute pain management in opioid dependent patients
Roura Turet Neurobiology of drug addiction: animal behavioral paradigms, and MDPV as an example of addictive cathinones
JP2005518429A (ja) 認知機能障害の治療のためのニコチン受容体の調節因子の使用
Yang et al. Vasopressin Produces Inhibition on Phrenic Nerve Activity and Apnea through V~ 1~ A Receptors in the Area Postrema in Rats

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130227